BIGBEAR
PHARMACEUTICAL
Deucravacitinib Tablets are a first-in-class oral selective tyrosine kinase 2 (TYK2) inhibitor and are deuterated targeted film-coated tablets.
AuthenticGuaranteeFast DeliveryPrivacy Bristol-Myers Squibb (BMS) recently announced that the pivotal Phase 3 POETYK PSO-1 study evaluating the novel anti-inflammatory drug deucravacitinib ···【More】
Update: 31 Mar,2026Source: BigbearViews: 106
On September 9, 2022, Bristol-Myers Squibb announced that the US Food and Drug Administration (FDA) has approved Sotyktu (deucravacitinib) for the tre···【More】
Update: 31 Mar,2026Source: BigbearViews: 97
On September 9, 2022, Bristol-Myers Squibb announced that the US Food and Drug Administration (FDA) has approved Sotyktu (deucravacitinib) for the tre···【More】
Update: 31 Mar,2026Source: BigbearViews: 98
Bristol-Myers Squibb announced on September 9, 2022, that the U.S. Food and Drug Administration (FDA) has approved Sotyktu (deucravacitinib) for the t···【More】
Update: 31 Mar,2026Source: BigbearViews: 104
The European Commission (EC) recently approved Bristol-Myers Squibb's Sotyktu (deucravacitinib) as a once-daily oral tablet for the treatment of a···【More】
Update: 31 Mar,2026Source: BigbearViews: 109
Bristol-Myers Squibb recently announced that the US Food and Drug Administration (FDA) has approved Sotyktu (deucravacitinib) for the treatment of act···【More】
Update: 31 Mar,2026Source: BigbearViews: 91
FDA Approval AnnouncementOn September 9, 2022, Bristol-Myers Squibb announced that the U.S. Food and Drug Administration (FDA) approved Sotyktu (deucr···【More】
Update: 23 Mar,2026Source: BigbearViews: 92
European Commission Approval AnnouncementThe European Commission (EC) has approved Sotyktu (deucravacitinib) from Bristol-Myers Squibb (BMS) as a once···【More】
Update: 23 Mar,2026Source: BigbearViews: 90
Overview of a First-in-Class Oral InnovationBristol Myers Squibb has announced the U.S. Food and Drug Administration (FDA) approval of Sotyktu™ (deucr···【More】
Update: 23 Mar,2026Source: BigbearViews: 95
Overview of Regulatory MilestoneOn March 6, 2026, Bristol Myers Squibb announced that the U.S. Food and Drug Administration (FDA) has approved Sotyktu···【More】
Update: 23 Mar,2026Source: BigbearViews: 86
Regulatory Approval OverviewOn Wednesday, March 11, 2026, the U.S. Food and Drug Administration (FDA) granted approval for Sotyktu (deucravacitinib). ···【More】
Update: 23 Mar,2026Source: BigbearViews: 86
Copyright2024@ BIGBEAR All right reserved Bigbear | Bigbear Pharmaceutical | Bigbear Laos
